ReviewTranslational lung cancer research2026
From biology to the clinic: research evidence and therapeutic advances of TROP2-targeted antibody-drug conjugates in small cell lung cancer.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trophoblast cell surface antigen 2 (TROP2) is a type I transmembrane glycoprotein that was initially identified in studies related to trophoblastic cells and has been implicated in epithelial cell proliferation and the maintenance of cellular stemness. While TROP2 is expressed at low levels in normal epithelial tissues, it is markedly overexpressed in a wide range of malignancies, including small cell lung cancer (SCLC), where it plays a critical role in promoting tumor cell proliferation, invasion, and metastasis. SCLC is characterized by aggressive biological behavior, early dissemination, and rapid development of therapeutic resistance. Despite improvements in first-line outcomes achieved with the combination of immunotherapy and chemotherapy, patients with relapsed or refractory disease continue to face low response rates, high recurrence, and substantial treatment-related toxicity. With antibody-drug conjugates (ADCs) targeting human epidermal growth factor receptor 2 (HER2) demonstrating clear clinical benefit in HER2-mutant non-small cell lung cancer (NSCLC), the tumor-selective overexpression of TROP2 relative to normal tissues has positioned it as an attractive target for ADC-based therapy. TROP2-targeted ADCs therefore represent an innovative therapeutic strategy and offer new promise for the treatment of SCLC. In this review, we systematically summarize the biological characteristics of TROP2 and the emerging clinical evidence supporting TROP2-directed ADCs in SCLC. We further propose an application framework integrating TROP2 expression levels, SCLC molecular subtypes, and DNA damage response (DDR) status, and discuss future research directions, including deeper characterization of TROP2 biology, optimization of combination strategies with immunotherapy and DDR-targeted agents, and the development of precision treatment approaches based on standardized TROP2 assessment and relevant biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.